Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839305 | 0.82 | XDH (0.51) | XDHDPP4SMN1; SMN2KDM4ETMIGD3 | |
| SCHEMBL16146535 | 0.82 | XDH (0.56) | XDHDPP4SMN1; SMN2KDM4ETMIGD3 | |
| SCHEMBL27397766 | 0.82 | XDH (0.51) | XDHDPP4SMN1; SMN2KDM4ETMIGD3 | |
| SCHEMBL30846558 | 0.76 | PDE4A (0.50) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B | |
| SCHEMBL5935896 | 0.76 | CDK2 (0.61) | XDHDPP4SMN1; SMN2KDM4ETMIGD3 | |
| SCHEMBL37384 | 0.75 | DPP4 (0.66) | XDHDPP4SMN1; SMN2KDM4ETMIGD3 | |
| Hydrochloric Acid SCHEMBL4763244 | 0.73 | DPP4 (0.63) | XDHDPP4SMN1; SMN2KDM4ETMIGD3 | |
| SCHEMBL11456967 | 0.73 | DPP4 (0.63) | XDHDPP4SMN1; SMN2KDM4ETMIGD3 | |
| SCHEMBL8719273 | 0.73 | DPP4 (0.63) | XDHDPP4SMN1; SMN2KDM4ETMIGD3 | |
| SCHEMBL24500763 | 0.72 | XDH (0.56) | XDHDPP4SMN1; SMN2KDM4ETMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027151-A1 | Heterocyclic compounds | NRAS, OXER1, HCRTR2 | XDH 728/4885DPP4 4696/4885SMN1; SMN2 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.